跳到正文
原文
MedPage Today·· 3 天前精选AI 评分64

CBD 对有智力障碍儿童的行为问题无效

CBD Didn't Top Placebo for Behavioral Problems in Kids With Intellectual Disability

AI 导读

一项随机对照试验显示,CBD 对有智力障碍和严重行为问题的儿童无效,与安慰剂效果相似。研究还指出,纯 CBD 对于有自闭症谱系障碍的儿童也无明显疗效。

推荐理由

研究结果显示 CBD 对于有智力障碍和严重行为问题的儿童无效,强调了需要谨慎解读新型治疗方法的效果。

正文 · 原文

— Randomized controlled trial adds to evidence of lack of benefit

by Rachael Robertson, Enterprise & Investigative Writer, MedPage Today

November 16, 2026 • 3 min read

  • Among kids with intellectual disability and severe behavioral problems, cannabidiol (CBD) and placebo resulted in similar improvements on parent-reported behavioral assessments.
  • Editorialists say these findings, combined with past trials, show that CBD does not benefit youths with intellectual disability or autism spectrum disorder.
  • Research exploring CBD in combination with other medicinal cannabis compounds may demonstrate different therapeutic effects.

Cannabidiol (CBD) was no better than placebo for treating severe behavioral problems in kids with intellectual disabilities, a randomized clinical trial in Australia showed.

In an intention-to-treat analysis, patients randomized to CBD had similar behavioral improvement to those who received placebo as measured on the Aberrant Behavior Checklist, Irritability (ABC-I), which captures irritability, aggression, and self-injurious behavior as measured by parent reporting, reported Daryl Efron, MD, of The Royal Children's Hospital in Victoria, Australia, and colleagues.

Over 8 weeks of treatment, ABC-I scores fell from 32.2 to 21.7 in the CBD group and from 30.0 to 19.2 in the placebo group, resulting in a mean difference of 2.4 (95% CI −1.5 to 6.3), they reported in JAMA Pediatrics.

Moreover, rates of adverse events were similar between groups, with 63.1% of those in the CBD group and 60.6% of those in the placebo group experiencing at least one adverse event, the researchers reported.

And there was no advantage for CBD over placebo in any subgroup analysis, including among patients with a diagnosis of autism spectrum disorder (ASD), who accounted for 84% of trial participants.

"The results suggest that CBD should not be used to treat severe behavioral problems in this population," Efron and team wrote.

In an accompanying editorial, Adi Aran, MD, and Dalit Cayam-Rand, MD, both of Shaare Zedek Medical Center in Jerusalem, Israel, noted that the findings were similar to those of a North American multicenter trial conducted among youths ages 6 to 17 years with ASD.

"Together, these findings suggest that the lack of benefit of purified CBD is not confined to youths with intellectual disability but extends to youths with ASD across a broad range of cognitive abilities," they wrote, pointing to an additional two trials of youths with ASD that showed no behavioral benefit for CBD.

Overall, the trials demonstrate "the magnitude of the placebo response even among youths with intellectual disability," which "underscores the need for considerable caution when interpreting apparent benefits of novel treatments based on uncontrolled studies or clinical experience," they wrote.

Finally, Aran and Cayam-Rand noted that "this may not be the end of the story for medical cannabis for youths with neurodevelopmental disorders," as ongoing research is evaluating CBD combined with other parts of the cannabis plant such as terpenes and small amounts of tetrahydrocannabinol.

The parallel design, double-blind, placebo-controlled randomized trial by Efron and colleagues took place from May 11, 2021 to May 8, 2025 across three children's hospitals in Australia. Youths between the ages of 6 and 18 with an intellectual disability and severe behavioral problems were eligible. Intellectual disability was defined as an IQ of less than 70 within 2 years of enrollment and a deficit in adaptive functioning.

In all, 132 patients were randomized 1:1 to either placebo or to 10 mg/kg/d CBD isolate in oil, both taken orally for 8 weeks, and then a 4-week follow-up. Eight patients were either lost to follow up, randomized in error, or had incomplete answers, and 17 discontinued treatment, resulting in 61 patients in the CBD group and 63 in the placebo group.

Three-quarters of patients were male and the mean age was 11.2 years. Most patients were taking a concomitant psychotropic medication at baseline (87%).

Parent-reported scores on the ABC-I subscale assessed at 8 weeks was the primary outcome. Exploratory outcomes included the four remaining subscales of the ABC (social withdrawal, stereotypic behavior, hyperactivity or noncompliance, and inappropriate speech), as well as anxiety, participation in activities, sleep, parenting stress, and parent mental health.

Efron and colleagues noted the study was limited by its heterogenous study sample. Plus, the fixed-dose of 10 mg/kg/d CBD was based on a pediatric epilepsy study, but other research has used smaller doses. While authors believe this dose was adequate to identify a treatment effect, it's also possible that behavioral effects could occur at lower doses, they noted.

来源:MedPage Today · medpagetoday.com